//=time() ?>
The combination of BRAF mutations and low EGFR expression makes patients with colon neuroendocrine carcinomas good candidates for clinical BRAF inhibition. https://t.co/JUEwLRRfOr
Metastatic Breast Cancer: TIL it's too late. https://t.co/lUvx6URTXJ